Non-small cell lung cancer
Not yet recruitingIvonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial
Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial
- Disease:Non-small cell lung cancer
- Substances:CarboplatinIvonescimab+2
Germany- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:European Organisation For Research And Treatment Of Cancer










